[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today

Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today

HALO : 69.82 (+5.34%)
Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions

Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions

HALO : 69.82 (+5.34%)
3 Growth Stocks Set to Flourish

3 Growth Stocks Set to Flourish

CECO : 79.47 (+1.27%)
TOST : 25.07 (-4.86%)
HALO : 69.82 (+5.34%)
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know

Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know

COLL : 31.06 (+1.90%)
TMO : 473.95 (-1.69%)
XRAY : 9.64 (-1.93%)
HALO : 69.82 (+5.34%)
Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO)

Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO)

HALO : 69.82 (+5.34%)
HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook

HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook

HALO : 69.82 (+5.34%)
Halozyme Therapeutics Q1 Earnings Call Highlights

Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced...

HALO : 69.82 (+5.34%)
Halozyme Therapeutics: Q1 Earnings Snapshot

Halozyme Therapeutics: Q1 Earnings Snapshot

HALO : 69.82 (+5.34%)
Halozyme Therapeutics’s (NASDAQ:HALO) Q1 CY2026 Sales Top Estimates

Halozyme Therapeutics’s (NASDAQ:HALO) Q1 CY2026 Sales Top Estimates

HALO : 69.82 (+5.34%)
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

Announcing New $1 billion Share Repurchase Program Projecting to Buy Back at Least $400 million in 2026

HALO : 69.82 (+5.34%)

Barchart Exclusives

Dear Dividend Investors, Mark Your Calendars for June 23
FedEx is expected to announce its sixth consecutive dividend hike with Q4 results scheduled on 23 June. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.